Venclexta (venetoclax) / AbbVie, Roche, Walter and Eliza Hall Institute  >>  Phase 1
Welcome,         Profile    Billing    Logout  

190 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Venclexta (venetoclax) / Roche, AbbVie
NCT01794507: A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy

Checkmark Venclexta in combination with bortezomib + dexamethasone in MM at ASH 2016
Dec 2016 - Dec 2016: Venclexta in combination with bortezomib + dexamethasone in MM at ASH 2016
Checkmark Venclexta + bortezomib in MM at ASCO 2016
Jun 2016 - Jun 2016: Venclexta + bortezomib in MM at ASCO 2016
Checkmark ASCO 2016
More
Completed
1b
66
Europe, US, RoW
ABT-199, bortezomib, dexamethasone
AbbVie, Genentech, Inc.
Relapsed/Refractory Multiple Myeloma
07/19
07/19
NCT03797261: A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies

Terminated
1b
9
Europe, US, RoW
Venetoclax, ABT-199, AMG 176
AbbVie, Genentech, Inc., Amgen
Acute Myeloid Leukemia, Non-Hodgkin's Lymphoma, Diffuse Large B-cell Lymphoma
12/19
12/19
NCT02951117: A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment

Withdrawn
1b
0
RoW
Venetoclax, ABT-199, ABBV-838, Dexamethasone
AbbVie
Multiple Myeloma
07/20
04/21
NCT04274933: A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy

Terminated
1b
4
Europe, Japan, US
Venetoclax, Venclexta, ABT-199, Capecitabine
AbbVie
Breast Cancer, Cancer
10/20
10/20
NCT03441555: A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Completed
1b
36
Europe, US
Venetoclax, ABT-199, Alvocidib, Flavopiridol
AbbVie, Sumitomo Pharma Oncology, Inc.
Acute Myeloid Leukemia (AML)
01/21
01/21
NCT04274907: A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

Terminated
1b
2
US
Venetoclax, Venclexta, ABT-199, Pembrolizumab, Keytruda
AbbVie
Non Small Cell Lung Cancer, Cancer
02/21
02/21
NCT03357627: A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma

Completed
1b
43
Europe, Canada, US
TAK-659, Venetoclax
Calithera Biosciences, Inc
Lymphoma, Non-Hodgkin, Lymphoma, Large B-cell, Diffuse, Lymphoma, Follicular
08/21
08/21
NCT03625505: A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia

Completed
1b
61
US
Venetoclax, ABT-199, GDC-0199, Gilteritinib, ASP-2215
AbbVie, Astellas Pharma Inc, Genentech, Inc.
Acute Myeloid Leukemia (AML)
08/21
08/21
V-FAST master, NCT04075747: A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia

Completed
1b
57
US
CPX-351, Vyxeos, JZP351, Venetoclax, Venclexta, Midostaurin, Rydapt, Enasidenib, Idhifa
Jazz Pharmaceuticals
Acute Myeloid Leukemia
02/22
09/23
NCT04038437: A Trial of CPX-351 Lower Intensity Therapy (LIT) Plus Venetoclax as First Line Treatment for Subjects With AML

Checkmark Initiation of enrollment of P1b trial in combination with venclexta for AML
Oct 2019 - Oct 2019: Initiation of enrollment of P1b trial in combination with venclexta for AML
Completed
1b
35
US
CPX-351, Vyxeos, Venetoclax, Venclexta
Jazz Pharmaceuticals
Acute Myeloid Leukemia
04/22
09/22
M15-358, NCT02203773: Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)

Checkmark Approved by MHRA in UK for 1L AML based on VIALE-A study
Jun 2021 - Jun 2021: Approved by MHRA in UK for 1L AML based on VIALE-A study
Checkmark Approved in Great Britain for newly-diagnosed AML
Jun 2021 - Jun 2021: Approved in Great Britain for newly-diagnosed AML
Checkmark Approved in combination with azacitidine or decitabine for 1L AML
More
Terminated
1b
212
Europe, US, RoW
Posaconazole, ABT-199, Decitabine, Azacitidine
AbbVie, Genentech, Inc.
Acute Myelogenous Leukemia, Myelogenous Leukemia, Treatment Naive AML
06/22
06/22
M13-365, NCT01682616: A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Checkmark From P1b trial of venetoclax in combination with Rituxan for r/r CLL at ASH 2015
Dec 2015 - Dec 2015: From P1b trial of venetoclax in combination with Rituxan for r/r CLL at ASH 2015
Checkmark P1b data in combination with Rituxan for CLL at EHA 2015
Jun 2015 - Jun 2015: P1b data in combination with Rituxan for CLL at EHA 2015
Checkmark For relapsed/refractory CLL
More
Completed
1b
49
US, RoW
ABT-199, venetoclax, Rituximab
AbbVie, Genentech, Inc.
Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia
06/22
06/22
NCT03484520: A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Terminated
1b
48
Europe, US, RoW
Venetoclax, ABT-199, GDC-0199, Dinaciclib, MK-7965, SCH-727965
AbbVie, Merck Sharp & Dohme LLC
Cancer - Acute Myeloid Leukemia
12/22
12/22
M15-522, NCT02966782: A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)

Completed
1b
70
Europe, US, RoW
venetoclax, ABT-199, GDC-0199, azacitidine, Vidaza
AbbVie, Celgene; Genentech, Inc.
Myelodysplastic Syndromes (MDS)
04/23
04/23
NCT04655391: Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation

Withdrawn
1b
0
US
Bosutinib Monohydrate, 3-Quinolinecarbonitrile, 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-, Hydrate (1:1), Bosulif, SKI-606 Monohydrate, Decitabine, 5-Aza-2''-deoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Enasidenib Mesylate, 2-Methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol Methanesulfonate, 2-Propanol, 2-Methyl-1-((4-(6-(trifluoromethyl)-2-pyridinyl)-6-((2-(trifluoromethyl)-4-pyridinyl)amino)-1,3,5-triazin-2-yl)amino)-, Methanesulfonate (1:1), AG-221 Mesylate, CC-90007, Enasidenib Methanesulfonate, Idhifa, Gilteritinib Fumarate, ASP-2215 Hemifumarate, ASP2215 Hemifumarate, Gilteritinib Hemifumarate, Xospata, Glasdegib Maleate, Daurismo, PF 04449913 Maleate, Ivosidenib, AG-120, Tibsovo, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Acute Myeloid Leukemia
12/23
12/23
ITALLI001, NCT05054465: A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL

Not yet recruiting
1b
48
RoW
Navitoclax, Venetoclax
Israeli Medical Association, Rabin Medical Center, Sheba Medical Center, Rambam Health Care Campus, Tel Aviv Medical Center, Soroka University Medical Center, Shaare Zedek Medical Center, Hadassah Medical Center
Acute Lymphoblastic Leukemia
08/25
08/26
NCT04973618: Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML

Withdrawn
1b
0
NA
APVO436
Aptevo Therapeutics
AML
01/26
01/27
VICTORY study, ACTRN12622000308796: Short-course treatment with venetoclax prior to non-myeloablative conditioning allogeneic stem cell transplantation for patients with haematological malignancies.

Recruiting
1
18
 
Melbourne Health, The Commonwealth of Australia - Medical Research Future Fund (MRFF)
Acute leukaemia (myeloid and/or lymphoid, or biphenotypic), Myelodysplastic syndrome, Chronic lymphocytic leukaemia, B-cell non-Hodgkin lymphoma, Plasma cell myeloma, Hodgkin lymphoma
 
 
NCT01969682: A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199

Withdrawn
1
0
US
ABT-199, GDC-0199, Rifampin
AbbVie, Genentech, Inc.
Non-Hodgkin's Lymphoma
05/14
05/14
NCT01969669: A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199

Completed
1
12
US
ABT-199, GDC-0199, Ketoconazole
AbbVie, Genentech, Inc.
Non-Hodgkin's Lymphoma
09/14
09/14
NCT02095574: A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma

Withdrawn
1
0
US
[14C]ABT-199 (GDC-0199)
AbbVie, Genentech, Inc.
Relapsed/Refractory Non-Hodgkin's Lymphoma
09/14
01/15
NCT02339181: A Study of GDC-0199 (ABT-199) in Combination With Obinutuzumab in Patients With Chronic Lymphocytic Leukemia

Recruiting
1
70
US, Europe
GDC-0199 (ABT-199), Obinutuzumab
Hoffmann-La Roche, Accord Healthcare, Inc., AbbVie (prior sponsor, Abbott), Apotex Corporation, Alkem Laboratories Ltd
Lymphocytic Leukemia, Chronic
01/15
11/16
NCT01686555: A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)

Completed
1
97
US, Europe, RoW
ABT-199, Placebo
AbbVie (prior sponsor, Abbott)
Lupus Erythematosus
06/15
06/15
NCT01685892: A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia

Completed
1
82
Europe, US
Obinutuzumab, GA101; RO5072759, Venetoclax, ABT-199, GDC-0199
Genentech, Inc., AbbVie (prior sponsor, Abbott)
Lymphocytic Leukemia, Chronic
05/18
08/19
NCT03343678: This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax

Withdrawn
1
0
NA
Venetoclax, BI 836826
Boehringer Ingelheim
Leukemia, Lymphocytic, Chronic, B-Cell
05/18
11/20
NCT01671904: A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Checkmark Venclexta +Gazyva + Rituxan +/- bendamustine in relapsed/refractory CLL at ASH 2016
Dec 2016 - Dec 2016: Venclexta +Gazyva + Rituxan +/- bendamustine in relapsed/refractory CLL at ASH 2016
Checkmark P1 data
Sep 2012 - Sep 2012: P1 data
Completed
1
84
Europe, US
Bendamustine, Obinutuzumab, GA101; RO5072759, Rituximab, MabThera; Rituxan, Venetoclax, ABT-199; GDC-0199
Genentech, Inc., AbbVie (prior sponsor, Abbott)
Chronic Lymphocytic Leukemia
08/18
08/20
NCT03255096: A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6

Checkmark Initial data from the trial for r/r DLBCL and/or high-grade B-cell lymphoma at ICML 2019
Jun 2019 - Jun 2019: Initial data from the trial for r/r DLBCL and/or high-grade B-cell lymphoma at ICML 2019
Completed
1
39
Europe, US, RoW
RO6870810, Venetoclax, Rituximab
Hoffmann-La Roche
Diffuse Large B-cell Lymphoma, High-Grade B-cell Lymphoma
07/19
07/19
NCT02391480: A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer

Completed
1
128
US
ABBV-075, Mivebresib, Venetoclax, Venclexta
AbbVie
Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Acute Myeloid Leukemia (AML), Multiple Myeloma, Prostate Cancer, Small Cell Lung Cancer, Non-Hodgkins Lymphoma
07/19
07/19
NCT03000660: Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis

Terminated
1
3
US
Venetoclax, ABT-199, Dexamethasone, Ozurdex, Maxidex, Baycadron
Tufts Medical Center
AL Amyloidosis
10/19
10/19
NCT01969695: An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma

Completed
1
11
US
ABT-199, GDC-0199
AbbVie, Genentech, Inc.
Non-Hodgkin's Lymphoma
12/19
12/19
NCT03884972: Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor

Withdrawn
1
0
US
Trabectedin, Ecteinascidin, ecteinascidin 743, ET-743, Yondelis, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
03/20
03/20
SAKK 35/15, NCT02877550: Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients

Completed
1
25
Europe
Obinutuzumab, GA101, Gazyvaro, Gazyva, Venetoclax, ABT-199, GDC-0199, Venclexta
Swiss Group for Clinical Cancer Research
Follicular Lymphoma
04/20
05/22
NCT01328626: A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

Checkmark EHA 2016
May 2016 - May 2016: EHA 2016
Checkmark EHA 2016
May 2016 - May 2016: EHA 2016
Checkmark In relapsed/refractory CLL and relapsed/refractory NHL at ASCO 2016
More
Completed
1
222
US, RoW
ABT-199
AbbVie, Genentech, Inc.
Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
05/20
05/20
NCT01594229: A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma

Checkmark Venclexta in combination with bendamustine and rituximab in r/r NHL
Jun 2017 - Jun 2017: Venclexta in combination with bendamustine and rituximab in r/r NHL
Checkmark Preliminary results of venetoclax+BR in R/R NHL at ICML 2015
Jun 2015 - Jun 2015: Preliminary results of venetoclax+BR in R/R NHL at ICML 2015
Checkmark ASCO 2015
More
Completed
1
60
US
ABT-199, Rituximab, Bendamustine
AbbVie, Genentech, Inc.
Non-Hodgkin's Lymphoma
07/20
07/20
NCT01742988: Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma

Checkmark For r/r DLBCL, DH/DE lymphoma in combination with venetoclax
Dec 2019 - Dec 2019: For r/r DLBCL, DH/DE lymphoma in combination with venetoclax
Checkmark DLBCL
Sep 2017 - Sep 2017: DLBCL
Checkmark ASH 2013
More
Completed
1
106
US
fimepinostat, CUDC-907, Rituximab, venetoclax
Curis, Inc., The Leukemia and Lymphoma Society
Lymphoma, Relapsed Lymphoma, Refractory Lymphoma, Relapsed and/or Refractory Lymphoma, Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL), Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Double-hit Lymphoma (DHL), Triple-hit Lymphoma (THL), Double-expressor Lymphoma (DEL), High-grade B-cell Lymphoma (HGBL)
10/20
10/20
NCT03194932: Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage

Completed
1
62
US
Venetoclax, Venclextra®, ABT-199, Cytarabine, Cytosine arabinoside, Ara-C, Cytosar®, Idarubicin, Idamycin PFS, Intrathecal Triple Therapy, ITMHA, methotrexate/hydrocortisone/cytarabine, Azacitidine, VIDAZA®
St. Jude Children's Research Hospital, Gateway for Cancer Research
Acute Myeloid Leukemia
10/20
06/22
NCT04422210: A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

Terminated
1
2
Europe, US, RoW
Venetoclax, Atezolizumab, Carboplatin, Etoposide
Hoffmann-La Roche
Small Cell Lung Cancer
11/20
11/20
NCT03181126 / 2017-001541-26: A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma

Completed
1
69
US, RoW
Navitoclax, ABT-263, Chemotherapy, Venetoclax, ABT-199 GDC-0199
AbbVie
Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma
11/20
11/20
NCT02670044 / 2015-003386-28: A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy

Checkmark From trial in combination with Idasanutlin for AML at ASH 2019
Dec 2019 - Dec 2019: From trial in combination with Idasanutlin for AML at ASH 2019
Checkmark From P1b/2 trial in combination with idasanutlin for r/r AML
Dec 2018 - Dec 2018: From P1b/2 trial in combination with idasanutlin for r/r AML
Completed
1
88
Europe, Canada, US
Cobimetinib, Idasanutlin, Venetoclax
Hoffmann-La Roche
Leukemia, Myeloid, Acute
12/20
12/20
NCT04171791: A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL)

Completed
1
4
US
ABT-199 (venetoclax)
Yale University
CTCL
02/21
06/21
NCT02419560: Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL

Completed
1
37
US
ABT-199 and Ibrutinib Combination, GDC-0199, venetoclax, PCI-32765
Craig Portell, MD, AbbVie
Lymphoma, Mantle-Cell, Recurrent Lymphoma, Mantle-Cell
05/21
05/21
SAKK 66/18, NCT03886649: Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.

Terminated
1
7
Europe
Copanlisib, Venetoclax
Swiss Group for Clinical Cancer Research
Non-Hodgkin Lymphoma
05/21
03/22
ACE-CL-003, NCT02296918: Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

Hourglass Jul 2022 - Dec 2022 : Data from trial for CLL/SLL/PLL
Checkmark From ACE-CL-003 trial in CLL/SLL/PLL
Jul 2021 - Jul 2021: From ACE-CL-003 trial in CLL/SLL/PLL
Checkmark Last patient dosing in P1 trial of acalabrutinib + obinutuzumab in CLL/SLL/PL
Feb 2019 - Feb 2019: Last patient dosing in P1 trial of acalabrutinib + obinutuzumab in CLL/SLL/PL
Completed
1
69
US
acalabrutinib, ACP-196, Obinutuzumab, Gazyvaro, Venetoclax, ABT-199, Venclexta, GDC-0199, Rituximab, Rituxan
Acerta Pharma BV
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia
08/21
10/25
NCT03218683: Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.

Terminated
1
70
US
AZD5991, AZD5991 + Venetoclax
AstraZeneca
Relapsed or Refractory Acute Myeloid Leukemia (AML)
10/21
10/21
RIVe-CLL/SLL, NCT03639324: Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL

Withdrawn
1
0
NA
Dose combination 1-1, dose combination 1-2, Dose combination 1-3, dose combination 1-4, Sub-Trial: Dose combination 2-1, Sub-Trial: Dose combination 2-2
Virginia Commonwealth University, Gilead Sciences
Chronic Lymphocytic Leukemia, CLL, Relapsed CLL, Refractory Chronic Lymphocytic Leukemia, Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, SLL, Relapsed Small Lymphocytic Lymphoma, Refractory Small Lymphocytic Lymphoma
10/21
10/21
V+DA-EPOCH-R, NCT03036904: Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas

Checkmark In in combination with chemoimmunotherapy in aggressive B-cell lymphomas at ASCO 2020
Jun 2020 - Jun 2020: In in combination with chemoimmunotherapy in aggressive B-cell lymphomas at ASCO 2020
Completed
1
31
US
Venetoclax, Venclexta, Rituximab, Rituxan, IDEC-C2B8, chimeric anti-CD20 monoclonal antibody, Etoposide, VP-16, VePesid, etopophos, toposar, Vincristine Sulfate, LCR, VCR, Cyclophosphamide, cytoxan, Prednisone, Deltasone, Orasone, Paracort, Cortan, Doxorubicin Hydrochloride, Hydroxydaunomycin Hydrochloride, Hydroxydoxorubicin Hydrochloride
Weill Medical College of Cornell University, Genentech, Inc., Massachusetts General Hospital, M.D. Anderson Cancer Center
Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma
11/21
11/21
VENOBI-CNS, NCT04073147: Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma

Terminated
1
4
Europe
Venetoclax, Venclyxto, Obinutuzumab, Gazyvaro
Klinikum Stuttgart, University Hospital Freiburg
Primary CNS Lymphoma
11/21
11/21
NCT03399539: Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma

Completed
1
8
US
Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Ixazomib Citrate, MLN-9708, MLN9708, Ninlaro, Laboratory Biomarker Analysis, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta
Mayo Clinic, Multiple Myeloma Research Foundation
Recurrent Plasma Cell Myeloma, T(11;14)
12/21
02/24
NCT04214860: APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies

Completed
1
51
US
APR-246, Venetoclax, Azacitidine
Aprea Therapeutics
Myeloid Malignancy
01/22
01/22
NCT03082209: A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies

Completed
1
153
Europe, Japan, US
ABBV-621, Venetoclax, ABT-199, GDC-0199, Bevacizumab, FOLFIRI
AbbVie
Advanced Solid Tumors, Cancer, Hematologic Malignancies
01/22
01/22
NCT03000257: A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors

Completed
1
182
Europe, Canada, Japan, US, RoW
Venetoclax, Rovalpituzumab Tesirine, ABBV-181, Budigalimab
AbbVie
Advanced Solid Tumors
03/22
03/22
ACE-LY-106, NCT02717624: A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL

Checkmark Data from P1b trial for MCL
Nov 2022 - Nov 2022: Data from P1b trial for MCL
Active, not recruiting
1
72
Europe, US
Acalabrutinib in combination with BR, Acalabrutinib + BR, Acalabrutinib in combination with VR, Acalabrutinib + VR
Acerta Pharma BV, AstraZeneca
Mantle Cell Lymphoma (MCL)
06/22
08/27
NCI-2018-02448, NCT03751436: Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Completed
1
10
US
Enzalutamide, ASP9785, MDV3100, Xtandi, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta
Roswell Park Cancer Institute, AbbVie
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone, PSA Progression, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
07/22
08/23
NCT04810598: Study to Assess Adverse Events and the Movement of Oral Venetoclax Tablet Through the Body of Female Participants Aged 18-75 Years With Impaired Renal Function

Completed
1
12
US
Venetoclax, Venclexta, ABT-199, GDC-0199
AbbVie, Roche-Genentech
Renal Impairment, Renal Disease
08/22
08/22
NCT03136497: A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Terminated
1
10
US
400mg ABT-199, A-1195425.0, Venetoclax, Ibrutinib, PIC-32765, Imbruvica, Rituximab, Rituxan, 800mg ABT-199
Hackensack Meridian Health, Janssen Scientific Affairs, LLC, Genentech, Inc.
Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
11/20
11/20
ChiCTR2200058059: A prospective clinical study of Azacitidine combined with or without Venetoclax for the maintenance treatment of post-remission acute myeloid leukemia

Recruiting
1
80
 
Azacitidine ± Venetoclax
Peking University People's Hospital; Peking University People's Hospital, National Natural Science Foundation of China
Leukemia
 
 
NCT03739554: CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL

Completed
1
5
US
CYC065, Venetoclax, ABT-199
Cyclacel Pharmaceuticals, Inc.
Relapsed or Refractory Chronic Lymphocytic Leukemia
11/22
04/23
NCT04017546: CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS

Completed
1
14
US
CYC065, Venetoclax
Cyclacel Pharmaceuticals, Inc., M.D. Anderson Cancer Center
AML, MDS
11/22
04/23
NCT03236857 / 2017-000439-14: A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

Completed
1
143
Europe, Canada, US, RoW
chemotherapy, venetoclax, ABT-199, GDC-0199, Venclexta
AbbVie, Roche-Genentech
Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Non-Hodgkin's Lymphoma, Neuroblastoma
04/23
04/23
ChiCTR2200064901: To assess the safety and efficacy of homoharringtonine, cytarabine, and G-CSF in combination with venetoclax (HAGV) in the treatment of childhood acute myeloid leukemia

Not yet recruiting
1
 
Children's Hospital of Soochow University; Children's Hospital of Soochow University, Suzhou Government and Children's Hospital of Soochow University
Initial acute myeloid leukemia
 
 
ASPEN-05, NCT04755244: A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia

Hourglass Jan 2023 - Dec 2023 : Data from ASPEN-05 trial in combination with venetoclax and azacitidine for AML
Checkmark Data from P1 portion of ASPEN-05 trial in combination with venetoclax and azacitidine for AML at ASH 2022
Dec 2022 - Dec 2022: Data from P1 portion of ASPEN-05 trial in combination with venetoclax and azacitidine for AML at ASH 2022
Checkmark Data from ASPEN-05 trial in combination with venetoclax and azacitidine for AML at ASH 2022
Dec 2022 - Dec 2022: Data from ASPEN-05 trial in combination with venetoclax and azacitidine for AML at ASH 2022
More
Terminated
1
14
US
evorpacept, ALX148, venetoclax, Venclexta, azacitidine, Vidaza
ALX Oncology Inc.
Acute Myeloid Leukemia, AML, Adult
05/23
08/23
NCT04912063: Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome

Terminated
1
40
Europe, Japan, US, RoW
Lemzoparlimab, TJ011133, ABBV-IMAB-TJC4, Azacitidine, Venetoclax, Venclexta, Venclyxto, ABT-199, GDC-0199
AbbVie
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
05/23
05/23
NCT03672695: Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia.

Completed
1
37
Europe, US, RoW
S 64315 (also referred as MIK665) and venetoclax
Institut de Recherches Internationales Servier, ADIR, a Servier Group company
Acute Myeloid Leukaemia
11/22
05/23
LOXO-IDH-20001, NCT04603001: Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

Active, not recruiting
1
260
Europe, Canada, US, RoW
LY3410738, Venetoclax, Azacitidine
Eli Lilly and Company, Loxo Oncology, Inc.
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasms (MPNs)
07/23
05/26
SELCLAX, NCT04898894: Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Active, not recruiting
1
37
US
Venetoclax, Venclextra®, ABT-199, Selinexor, KPT-330, Cytarabine, Cytosine arabinoside, Ara-C, Cytosar®, Fludarabine, Fludara®, Fludarabine phosphate, 2-fluoro-ara-AMP, Filgrastim, G-CSF, Methotrexate, MTX, amethopterin, Trexall®, methotrexate/hydrocortisone/cytarabine, ITMHA, Intrathecal triples
St. Jude Children's Research Hospital, Karyopharm Therapeutics Inc, AbbVie, Gateway for Cancer Research
Acute Leukemia of Ambiguous Lineage in Relapse, Acute Myeloid Leukemia, in Relapse, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Myeloid Leukemia
07/23
02/26
NCT03422393: Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib

Active, not recruiting
1
24
US
Venetoclax, Venclexta, Ibrutinib, Imbruvica
Michael Choi, Pharmacyclics LLC.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
08/24
08/28
NCT05909553: Study to Assess Adverse Events and Compare How Crushed, Ground, and Intact Oral Tablets Venetoclax Moves Through the Body of Healthy Female Adult Volunteers

Completed
1
15
US
Venetoclax, ABT-199, Venclaxta
AbbVie
Healthy Volunteers
09/23
09/23
NCT05774886: Implantable Microdevice for TNBC - Pilot Study

Withdrawn
1
24
NA
Implantable Microdevice (IMD)
Dana-Farber Cancer Institute
Triple Negative Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer, Early Stage Triple-Negative Breast Carcinoma, Breast Neoplasms, Breast Carcinoma
09/23
09/28
NCT04070768: Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113

Completed
1
18
US
Gemtuzumab Ozogamicin, GO, Venetoclax
John Quigley, Pfizer, AbbVie
Acute Myeloid Leukemia
10/23
02/24
NCT04336982: A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia

Terminated
1
22
Europe, Canada, US
CC-90009, Venetoclax, Azacitidine, Gilteritinib
Celgene, AbbVie
Leukemia, Myeloid, Acute
10/23
04/24
NCT03063944: STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy

Completed
1
37
US
STAT Inhibitor OPB-111077, OPB-111077, Decitabine, 2'-Deoxy-5-azacytidine, 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one, 2353-33-5, 5-Aza-2'-deoxycytidine, 5-Aza-2'deoxycytidine, 5-Aza-2-deoxycytidine, 5-Azadeoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Venetoclax, 1257044-40-8, 4-(4-((2-(4-Chlorophenyl)-4, 4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto, Laboratory Biomarker Analysis
Sidney Kimmel Cancer Center at Thomas Jefferson University, Otsuka America Pharmaceutical
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
01/24
03/24
NCT03713580: Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma

Active, not recruiting
1
25
US
Venetoclax
Case Comprehensive Cancer Center
Non-hodgkin Lymphoma
12/25
12/25
NCT03955783: Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies

Completed
1
78
US
Venetoclax, Selinexor
Sanjay Mohan, Karyopharm Therapeutics Inc, AbbVie
Diffuse Large B-cell Lymphoma, Acute Myeloid Leukemia, Non-Hodgkin's Lymphoma
09/24
09/24
NCT03940352: HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

Terminated
1
52
Europe, US, RoW
HDM201, MBG453, Venetoclax
Novartis Pharmaceuticals
Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS)
08/24
08/24
IO-202-CL-001, NCT04372433: IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML

Completed
1
67
US
IO-202, IO-202 and Azacitidine, IO-202 and AZA, IO-202 and Azacitidine + Venetoclax, IO-202 and AZA + Ven
Immune-Onc Therapeutics, California Institute for Regenerative Medicine (CIRM)
AML With Monocytic Differentiation, CMML
01/25
01/25
NCT04512105: Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia

Completed
1
6
US
Pitavastatin, LIVALO®, Venetoclax, VENCLEXTA®
University of California, Irvine, United States Department of Defense
Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, AML, Adult, CLL, CLL, Relapsed, CLL, Refractory
07/24
02/25
NCT03969446: Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory

Recruiting
1
54
US
Decitabine, 5-Aza-2'-deoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
City of Hope Medical Center, National Cancer Institute (NCI)
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
02/26
02/26
NCT05222984: Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax

Active, not recruiting
1
17
US
Decitabine, 5-Aza-2'-deoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Navitoclax, A-855071.0, ABT-263, BcI-2 Family Protein Inhibitor ABT-263, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
04/26
04/26
NCT02992522: Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Active, not recruiting
1
22
US
Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta
Beth Christian, Celgene, Genentech, Inc.
B-Cell Lymphoma, Unspecified, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Transformed Recurrent Non-Hodgkin Lymphoma, B-Cell
08/26
08/26
NCT03041688: Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia

Active, not recruiting
1
58
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Decitabine, 5-Aza-2'-deoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Navtemadlin, (3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-((1S)-2-methyl-1-(((1-methylethyl)sulfonyl)methyl)propyl)-2-oxo-3-piperidineacetic Acid, AMG 232, AMG-232, KRT 232, KRT-232, KRT232, MDM2 Inhibitor KRT-232, Venetoclax, ABT 199, ABT-0199, ABT-199, ABT199, GDC 0199, GDC-0199, GDC0199, RG7601, Venclexta, Venclyxto
National Cancer Institute (NCI)
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
06/26
06/26
NCI-2019-03272, NCT03874052: Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
1
51
US
Azacitidine, 5 AZC, 5-AC, 5-Azacitidine, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Echocardiography Test, EC, Echocardiography, Punch Biopsy, BIOPSY, PUNCH, Punch Biopsy of Skin, Questionnaire Administration, Ruxolitinib, INCB 018424, INCB-018424, INCB-18424, INCB18424, Oral JAK Inhibitor INCB18424, Venetoclax, ABT 199, ABT-0199, ABT-199, ABT199, GDC 0199, GDC-0199, GDC0199, RG7601, Venclexta, Venclyxto
Jennifer Saultz, AbbVie, Incyte Corporation, Oregon Health and Science University
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Secondary Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Refractory Secondary Acute Myeloid Leukemia
12/27
12/27
CCTG LY18-A, NCT04161248: Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Recruiting
1
18
Canada
Venetoclax, Rituximab Injection, Rituximab SC, Gemcitabine, Dexamethasone, Cisplatin, Glofitamab, Tafasitamab
Canadian Cancer Trials Group, Roche Pharma AG, AbbVie, Incyte Corporation
Lymphoma, B-Cell
12/25
07/26
NCT03709758: Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML

Active, not recruiting
1
50
US
Venetoclax, Venclexta, Daunorubicin, Cerubidine, Cytarabine, Cytosar-U
Dana-Farber Cancer Institute, AbbVie, Genentech, Inc.
Acute Myeloid Leukemia
02/25
06/26
NCT05053659: Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma

Recruiting
1
36
US
Loncastuximab tesirine, ADCT-402, lonca, Venetoclax, ABT-199, GDC-0199
Paolo Caimi, MD
Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
12/25
06/26
ChiCTR2200065634: One arm open phase I clinical study of Venetoclax combined with CACAG regimen in the treatment of acute myeloid leukemia

Recruiting
1
30
 
1.azacytidine (75mg/m2/day, days 1 to 7). 2.cytarabine (75mg/m2 bid, days 1 to 5). 3.aclamycin (10mg/m2/day, day1,3,5). 4.Chidamide (30mg/day , days 0,3). 5.venetoclax (100mg day 1, 200 mg day 2, 400mg days 3 to 14 ). 6.granulocyte colony-stimulating factor (5ug/kg/day, day 0 until agranulocytosis recovery
Chinese PLA General Hospital; Chinese PLA General Hospital, Fully self-raised
acute myeloid leukemia
 
 
NCT05976217: Safety and Efficacy of Venetoclax in Idiopathic Pulmonary Fibrosis

Completed
1
3
US
Venetoclax
University of Alabama at Birmingham
Idiopathic Pulmonary Fibrosis
03/24
03/24
NCT03485547: Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Active, not recruiting
1
5
US
Venetoclax, Venclexta
Dana-Farber Cancer Institute, AbbVie
Blastic Plasmacytoid Dendritic Cell Neoplasm
02/26
02/26
NCT03613532: Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

Active, not recruiting
1
102
US
Venetoclax, ABT199, Fludarabine, Fludara, Busulfan, Busulfex, Myleran, Azacitidine, Decitabine/cedazuridine
Jacqueline Garcia, MD, National Institutes of Health (NIH)
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), MDS/Myeloproliferative Neoplasm-unclassifiable (MDS/MPN-unclassifiable), Hematopoietic Stem Cell Transplant
05/26
03/27
SL03-OHD-104, NCT05275439: Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects with MDS or AML

Completed
1
106
Europe, Canada, US
SL-172154, Azacitidine (AZA), Venetoclax
Shattuck Labs, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
02/25
02/25
NCT06152809: CIML NK Cells With Venetoclax for AML

Recruiting
1
10
US
Cytokine-Induced Memory-like Natural Killer Cells, CIML NK Cells, Interleukin-2, Aldesleukin, Proleukin, IL-2, Venetoclax, C45H50ClN7O7S
Dana-Farber Cancer Institute, The Leukemia and Lymphoma Society
Acute Myeloid Leukemia, Acute Myeloid Leukemia Recurrent, Leukemia, Leukemia, Myeloid
11/26
11/27
BO42203, NCT04790903: A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Terminated
1
50
Europe, US
Venetoclax, Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone
Hoffmann-La Roche
Lymphoma, Large B-Cell, Diffuse
05/24
05/24
NCT06070948: A Study to Assess Food Effect of Venetoclax New Tablet Formulation in Healthy Female Participants

Withdrawn
1
72
US
Venetoclax
AbbVie
Healthy Volunteers
07/25
07/25
NCT04277442: Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia

Completed
1
1
US
Decitabine, 5-Aza-2'-deoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Venetoclax, ABT 199, ABT-0199, ABT-199, ABT199, GDC 0199, GDC-0199, GDC0199, RG7601, Venclexta, Venclyxto
National Cancer Institute (NCI)
Acute Myeloid Leukemia
05/20
09/22
NCT03557619: A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies

Recruiting
1
12
US, RoW
Venetoclax, ABT-199, GDC-0199, Venclexta, ethinyl estradiol/levonorgestrel, Levora
AbbVie
Hematologic Malignancies
03/26
03/26
NCT06191978: A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Recruiting
1
40
US
ASTX727, Inqovi, Venetoclax, ABT-199, GDC-0199
M.D. Anderson Cancer Center, Astex Pharmaceuticals, Inc.
Acute Myeloid Leukemia
12/28
12/28
TTI-622-01, NCT03530683: A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

Checkmark First patient dosed in combination with azacitidine for TP53-mutated AML
Aug 2021 - Aug 2021: First patient dosed in combination with azacitidine for TP53-mutated AML
Checkmark Data from trial for lymphoma
Apr 2021 - Apr 2021: Data from trial for lymphoma
Terminated
1
189
US
Maplirpacept (PF-07901801), SIRPα-IgG4 Fc, TTI-622, Azacitidine, VIDAZA, Venetoclax, VENCLEXTA, Carfilzomib, KYPROLIS, Dexamethasone, Anti-CD20 Targeting agent, Ruxience or Rituxan, Isatuximab, Sarclisa
Pfizer
Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Diffuse Large B-Cell Lymphoma
07/24
07/24
NCT04447716: An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment

Active, not recruiting
1
4
US
Venetoclax, 1257044-40-8,, 4-(4-((2-(4-Chlorophenyl)-4, 4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide,, ABT-0199,, ABT-199,, ABT199,, RG7601,, GDC-0199,, Lenalidomide, 191732-72-6,, 3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione,, 703813,, CC-5013, Revlimid, CC5013, CDC 501,, lenalidomide,, Rituximab, 174722-31-7,, 687451,, ABP 798,, BI 695500,, C2B8 Monoclonal Antibody,, Chimeric Anti-CD20 Antibody,, CT-P10,, IDEC-102,, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody,, MabThera,, Monoclonal Antibody IDEC-C2B8,, PF-05280586,, Rituxan,, Rituximab,, RITUX, Rituximab and Hyaluronidase Human, Rituxan Hycela,, Rituximab Plus Hyaluronidase,, Rituximab/Hyaluronidase,, Rituximab/Hyaluronidase Human
Thomas Jefferson University, Genentech, Inc.
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Follicular Lymphoma, Refractory Indolent Adult Non-Hodgkin Lymphoma, Refractory Marginal Zone Lymphoma
05/24
04/27
NCT05211336: Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System

Active, not recruiting
1
14
US
Obinutuzumab, Gazyva, Prednisone, Rayos, Deltasone, Prednisone Intensol, Lenalidomide, REVLIMID, Venetoclax, Venclexta, Venclyxto, Ibrutinib, Imbruvica, Acetaminophen, Tylenol, Ofirmev, FeverAll, Diphenhydramine, Benadryl, Banophen, Nytol, Peg-filgrastim, Neulasta, CT Scan (chest, abdomen, and pelvis), Computed tomography scan, MRI, Magnetic resonance imaging, 18f-FDG-PET, F18-fluorodeoxyglucose-positron emission tomography, PET, Lumbar puncture/Ommaya tap, Bone marrow aspiration/biopsy, EKG, Electrocardiogram
National Cancer Institute (NCI)
Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS
06/24
06/29
NCT06177067: Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Recruiting
1
24
US
Revumenib, SNDX-5613, Venetoclax, Venclextra®, Azacitidine, VIDAZA®, 5-azacitidine, intrathecal (IT) chemotherapy, ITMHA, methotrexate/hydrocortisone/cytarabine, Cytarabine, Ara-C, Cytosar®, Methotrexate, MTX, Trexall®
St. Jude Children's Research Hospital, Syndax Pharmaceuticals
Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Leukemia of Ambiguous Lineage
07/26
04/27
NCT03547115: A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML

Checkmark Data from trial for r/r B-cell malignancies or AML at ASH 2021
Nov 2021 - Nov 2021: Data from trial for r/r B-cell malignancies or AML at ASH 2021
Checkmark Initiation of combination trial in B cell malignancies
Jun 2018 - Jun 2018: Initiation of combination trial in B cell malignancies
Recruiting
1
100
US
voruciclib monotherapy, ME-522, voruciclib and venetoclax, VENCLEXTA®
MEI Pharma, Inc.
Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML)
04/24
03/25
 

Download Options